Table 1.
Descriptive characteristics of 3846 T2N0M0 bladder cancer patients treated with trimodal therapy identified within the Surveillance, Epidemiology, and End Results database (2000–2018).
| Variables | Overall (n = 3846) |
|---|---|
| Age at diagnosis (years) | |
| Median | 77 |
| IQR | 70–83 |
| Histology | |
| Urothelial Carcinoma | 3627 (94.3) |
| Neuroendocrine Carcinoma | 105 (2.7) |
| Squamous Cell Carcinoma | 85 (2.2) |
| Adenocarcinoma | 29 (0.8) |
| Grade | |
| Low grade | 113 (3) |
| High grade | 3733 (97) |
| Sex | |
| Male | 2842 (74) |
| Female | 1004 (26) |
| Tumor Site | |
| Trigone | 293 (7.7) |
| Dome | 201 (5.2) |
| Lateral wall | 871 (22.6) |
| Anterior wall | 139 (3.6) |
| Posterior wall | 328 (8.5) |
| Bladder neck | 139 (3.6) |
| Ureteral orifice | 76 (2) |
| Lateral-posterior wall | 585 (15.2) |
| NOS | 1214 (31.6) |
| Follow-up (months) | |
| Median | 21 |
| IQR | 10–46 |
IQR: interquartile range; NOS: not otherwise specified.